Skip to main content

Articles

316 result(s) for 'serum psa 29' within BMC Cancer

Page 4 of 7

  1. Androgen deprivation therapy (ADT) is the effective treating prostate cancer but is often accompanied by cancer treatment-induced bone loss (CTIBL), which impairs the patient’s quality of life. In patients wit...

    Authors: Daisuke Watanabe, Takahiro Kimura, Ken Watanabe, Hiromitsu Takano, Yuko Uehara, Tadaaki Minowa, Akemi Yamashita, Seiichiro Yoshikawa and Akio Mizushima
    Citation: BMC Cancer 2021 21:422
    Content type: Research Published on:

  2. Hormone therapy plus radiotherapy significantly decreases recurrences and mortality of patients affected by locally advanced prostate cancer. In order to determine if difference exists according to the hormona...

    Authors: Federica Cuppone, Emilio Bria, Diana Giannarelli, Vanja Vaccaro, Michele Milella, Cecilia Nisticò, Enzo Maria Ruggeri, Isabella Sperduti, Sergio Bracarda, Paola Pinnarò, Gaetano Lanzetta, Paola Muti, Francesco Cognetti and Paolo Carlini
    Citation: BMC Cancer 2010 10:675
    Content type: Research article Published on:

  3. The insulin-like growth factor-1 (IGF-1) plays an important role in growth of prostate cancer (PCa) cells and facilitating the development and progression of PCa. This study aimed to evaluate the association o...

    Authors: Norihiko Tsuchiya, Shintaro Narita, Takamitsu Inoue, Mitsuru Saito, Kazuyuki Numakura, Mingguo Huang, Shingo Hatakeyama, Shigeru Satoh, Seiichi Saito, Chikara Ohyama, Yoichi Arai, Osamu Ogawa and Tomonori Habuchi
    Citation: BMC Cancer 2013 13:150
    Content type: Research article Published on:

  4. Definitive radiation therapy (dRT) is an effective initial treatment of intermediate-risk (IR) and high-risk (HR) prostate cancer (PCa). PSMA PET/CT is superior to standard of care imaging (CT, MRI, bone scan)...

    Authors: Jeremie Calais, Shaojun Zhu, Nader Hirmas, Matthias Eiber, Boris Hadaschik, Martin Stuschke, Ken Herrmann, Johannes Czernin, Amar U. Kishan, Nicholas G. Nickols, David Elashoff and Wolfgang P. Fendler
    Citation: BMC Cancer 2021 21:512
    Content type: Study protocol Published on:

  5. Life expectancy of patients with metastatic castration-resistant prostate cancer (mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis of primary prostate cancer, 10–2...

    Authors: Sui wai Ling, Astrid A. M. van der Veldt, Mark Konijnenberg, Marcel Segbers, Eline Hooijman, Frank Bruchertseifer, Alfred Morgenstern, Erik de Blois and Tessa Brabander
    Citation: BMC Cancer 2024 24:146
    Content type: Study Protocol Published on:

  7. Prostate cancer (PCa), a leading cause of cancer death in North American men, displays a broad range of clinical outcome from relatively indolent to lethal metastatic disease. Several genomic alterations have ...

    Authors: Khalil Choucair, Joshua Ejdelman, Fadi Brimo, Armen Aprikian, Simone Chevalier and Jacques Lapointe
    Citation: BMC Cancer 2012 12:543
    Content type: Research article Published on:

  8. Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblas...

    Authors: Jeetendra Eswaraka, Anand Giddabasappa, Guangzhou Han, Kush Lalwani, Koleen Eisele, Zheng Feng, Timothy Affolter, James Christensen and Gang Li
    Citation: BMC Cancer 2014 14:742
    Content type: Research article Published on:

  9. To evaluate the impact of Gallium-68 [68Ga] labeled prostate specific membrane antigen (PSMA) positron emission tomography (PET)/X-ray computed tomography (CT) compared with conventional imaging on staging and cl...

    Authors: Maarten L. Donswijk, Pim J. van Leeuwen, Erik Vegt, Zing Cheung, Stijn W. T. P. J. Heijmink, Henk G. van der Poel and Marcel P. M. Stokkel
    Citation: BMC Cancer 2020 20:723
    Content type: Research article Published on:

  10. Current surgical and ablative treatment options for prostate cancer (PCa) may result in a high incidence of (temporary) incontinence, erectile dysfunction and/or bowel damage. These side effects are due to pro...

    Authors: Matthijs J. V. Scheltema, Willemien van den Bos, Daniel M. de Bruin, Hessel Wijkstra, M. Pilar Laguna, Theo M. de Reijke and Jean JMCH de la Rosette
    Citation: BMC Cancer 2016 16:299
    Content type: Study protocol Published on:

  11. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and circulating tumor cells (CTCs) have been associated with survival in castration-resistant prostate cancer (CRPC). However, no study h...

    Authors: Weelic Chong, Zhenchao Zhang, Rui Luo, Jian Gu, Jianqing Lin, Qiang Wei, Bingshan Li, Ronald Myers, Grace Lu-Yao, William Kevin Kelly, Chun Wang and Hushan Yang
    Citation: BMC Cancer 2021 21:655
    Content type: Research Published on:

  12. Prostate cancer is one of the leading causes of cancer death amongst men in economically advanced countries. The disease is characterized by a greatly varying clinical course, where some patients harbor non- o...

    Authors: Martin Mørck Mortensen, Søren Høyer, Torben Falck Ørntoft, Karina Dalsgaard Sørensen, Lars Dyrskjøt and Michael Borre
    Citation: BMC Cancer 2014 14:859
    Content type: Research article Published on:

  14. Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after attenuatio...

    Authors: William H Tu, Chunfang Zhu, Curtis Clark, James G Christensen and Zijie Sun
    Citation: BMC Cancer 2010 10:556
    Content type: Research article Published on:

  15. Cabazitaxel (CBZ) chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) is believed to be palliative because the radiological response rate is low and a durable response is rare. Here, we de...

    Authors: Takeo Kosaka, Hiroshi Hongo and Mototsugu Oya
    Citation: BMC Cancer 2019 19:562
    Content type: Case report Published on:

  16. Routine measurement of tumor markers is not recommended in daily clinical practice for patients with cancer of unknown primary (CUP). We evaluated the diagnostic value of tumor markers in identifying favorable...

    Authors: Shigemasa Takamizawa, Tatsunori Shimoi, Masayuki Yoshida, Momoko Tokura, Shu Yazaki, Chiharu Mizoguchi, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Emi Noguchi, Kazuki Sudo and Kan Yonemori
    Citation: BMC Cancer 2022 22:412
    Content type: Research Published on:

  17. Monocarboxylate transporters (MCTs) are transmembrane proteins involved in the transport of monocarboxylates across the plasma membrane, which appear to play an important role in solid tumours, however the rol...

    Authors: Nelma Pértega-Gomes, José R Vizcaíno, Vera Miranda-Gonçalves, Céline Pinheiro, Joana Silva, Helena Pereira, Pedro Monteiro, Rui M Henrique, Rui M Reis, Carlos Lopes and Fátima Baltazar
    Citation: BMC Cancer 2011 11:312
    Content type: Research article Published on:

  18. We aimed to evaluate relationships between clinical outcomes and explanatory variables by network clustering analysis using data from a post marketing surveillance (PMS) study of castration-resistant prostate ...

    Authors: Hirotaka Kazama, Osamu Kawaguchi, Takeshi Seto, Kazuhiro Suzuki, Hideyasu Matsuyama, Nobuaki Matsubara, Yuki Tajima and Taro Fukao
    Citation: BMC Cancer 2022 22:470
    Content type: Research Published on:

  19. The purpose of this study was to develop a functional clinical nomogram for predicting 8-year overall survival (OS) of patients with prostate cancer (PCa) primary based on peripheral lymphocyte.

    Authors: Jiayi Chen, Feng Yu, Ganyuan He, Wenke Hao and Wenxue Hu
    Citation: BMC Cancer 2024 24:254
    Content type: Research Published on:

  20. Muscle mass is important for metastatic prostate cancer survival and quality of life (QoL). The backbone of treatment for men with metastatic castration sensitive prostate cancer (mCSPC) is androgen deprivatio...

    Authors: Adriana M Coletta, Lea Haverbeck Simon, Kelsey Maslana, Sarah Taylor, Kish Larson, Pamela A Hansen, Vinay Mathew Thomas, Cornelia M Ulrich, Manish Kohli, Jonathan Chipman, Umang Swami, Sumati Gupta, Benjamin L Maughan and Neeraj Agarwal
    Citation: BMC Cancer 2024 24:493
    Content type: Study Protocol Published on:

  21. Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certain genes such as AMACR, EZH2, PSGR, PSMA and TRPM8 could be associated with an aberrant expression of non-coding microRNAs...

    Authors: Kati Erdmann, Knut Kaulke, Cathleen Thomae, Doreen Huebner, Mildred Sergon, Michael Froehner, Manfred P Wirth and Susanne Fuessel
    Citation: BMC Cancer 2014 14:82
    Content type: Research article Published on:

  22. Circulating tumor cell (CTCs) counts might serve as early surrogate marker for treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) patients. We prospectively assessed categorical and ...

    Authors: Mark Thalgott, Brigitte Rack, Matthias Eiber, Michael Souvatzoglou, Matthias M. Heck, Caroline Kronester, Ulrich Andergassen, Victoria Kehl, Bernd J. Krause, Jurgen E. Gschwend, Margitta Retz and Roman Nawroth
    Citation: BMC Cancer 2015 15:458
    Content type: Research article Published on:

  23. Prostate cancer (PCa) is characterized by clinical and biological heterogeneity and has differential outcomes and mortality rates. Therefore, it is necessary to identify molecular alterations to define new the...

    Authors: Caterina Mancarella, Irene Casanova-Salas, Ana Calatrava, Maria García-Flores, Cecilia Garofalo, Andrea Grilli, José Rubio-Briones, Katia Scotlandi and José Antonio López-Guerrero
    Citation: BMC Cancer 2017 17:367
    Content type: Research article Published on:

  24. Danish cancer patients have lower survival rates than patients in many other western countries. Half of the patients present with non-alarm symptoms and thus have a long diagnostic pathway. Consequently, an ur...

    Authors: Esben Næser, Henrik Møller, Ulrich Fredberg, Jan Frystyk and Peter Vedsted
    Citation: BMC Cancer 2017 17:817
    Content type: Research article Published on:

  25. GPR110 is an orphan G protein-coupled receptor--a receptor without a known ligand, a known signaling pathway, or a known function. Despite the lack of information, one can assume that orphan receptors have imp...

    Authors: Amy M Lum, Bruce B Wang, Gabriele B Beck-Engeser, Lauri Li, Namitha Channa and Matthias Wabl
    Citation: BMC Cancer 2010 10:40
    Content type: Research article Published on:

  26. Five-year survival for lung cancer has remained at 16% over last several decades largely due to the fact that over 50% of patients are diagnosed with locally-advanced or metastatic disease. Diagnosis at an ear...

    Authors: Elena Kupert, Marshall Anderson, Yin Liu, Paul Succop, Linda Levin, Jiang Wang, Kathryn Wikenheiser-brokamp, Pingping Chen, Susan M Pinney, Trudy Macdonald, Zhongyun Dong, Sandra Starnes and Shan Lu
    Citation: BMC Cancer 2011 11:513
    Content type: Research article Published on:

  27. Self-tests are those where an individual can obtain a result without recourse to a health professional, by getting a result immediately or by sending a sample to a laboratory that returns the result directly. ...

    Authors: Sue Wilson, Sheila Greenfield, Helen M Pattison, Angela Ryan, Richard J McManus, David Fitzmaurice, John Marriott, Cyril Chapman and Sue Clifford
    Citation: BMC Cancer 2006 6:215
    Content type: Study protocol Published on:

  28. The KHP PCaBB was established in 2013 and recruits donors from the Urology or Oncology Departments at Guy’s Hospital in London (UK). Prostate cancer patients may be approached to give their consent for biobank...

    Authors: S. R. Saifuddin, W. Devlies, A. Santaolalla, F. Cahill, G. George, D. Enting, S. Rudman, P. Cathcart, B. Challacombe, P. Dasgupta, C. Galustian, A. Chandra, S. Chowdhury, C. Gillett and M. Van Hemelrijck
    Citation: BMC Cancer 2017 17:784
    Content type: Database Published on:

  29. Solute Carrier Family 6 Member 1 (SLC6A1) has been identified as a cancer-promoting gene in various human cancers, such as clear cell renal cell carcinoma and ovarian cancer. However, its roles in prostate can...

    Authors: Chaojiang Chen, Zhiduan Cai, Yangjia Zhuo, Ming Xi, Zhuoyuan Lin, Funeng Jiang, Zezhen Liu, Yueping Wan, Yu Zheng, Jianxin Li, Xing Zhou, Jianguo Zhu and Weide Zhong
    Citation: BMC Cancer 2020 20:289
    Content type: Research article Published on:

  30. Increasing evidence suggests a close relationship between systemic inflammation and cancer development and progression. The neutrophil to lymphocyte ratio (NLR) has been shown to be an independent prognostic i...

    Authors: Houda Bahig, Daniel Taussky, Guila Delouya, Amal Nadiri, Ariane Gagnon-Jacques, Paule Bodson-Clermont and Denis Soulieres
    Citation: BMC Cancer 2015 15:594
    Content type: Research article Published on:

  31. Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic ...

    Authors: Pablo Sáenz-López, Rafael Carretero, José Manuel Cózar, José Maria Romero, Julia Canton, José Ramón Vilchez, Miguel Tallada, Federico Garrido and Francisco Ruiz-Cabello
    Citation: BMC Cancer 2008 8:382
    Content type: Research article Published on:

  32. Clinical trial (CT) participation may confer access to new, potentially active agents before their general availability. This study aimed to investigate the potential survival benefit of participation in inves...

    Authors: Kyo Chul Koo, Jong Soo Lee, Jong Won Kim, Kyung Suk Han, Kwang Suk Lee, Do Kyung Kim, Yoon Soo Ha, Koon Ho Rha, Sung Joon Hong and Byung Ha Chung
    Citation: BMC Cancer 2018 18:468
    Content type: Research article Published on:

  33. To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated ...

    Authors: Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, María José Méndez-Vidal, Alvaro Pinto, Ángel Rodríguez, José Miguel Cuevas Sanz, Jacobo Rodrigo Muñoz del Toro, Eduardo Useros Rodríguez, Ángela García García-Porrero and Sergio Vázquez
    Citation: BMC Cancer 2019 19:766
    Content type: Research article Published on:

  34. Breast cancer is a complex and heterogeneous disease at the molecular level. Evolution is difficult to predict according to classical histoclinical prognostic factors. Different studies highlight the importanc...

    Authors: Stéphanie Fabre-Lafay, Florence Monville, Sarah Garrido-Urbani, Carole Berruyer-Pouyet, Christophe Ginestier, Nicolas Reymond, Pascal Finetti, Richard Sauvan, José Adélaïde, Jeannine Geneix, Eric Lecocq, Cornel Popovici, Patrice Dubreuil, Patrice Viens, Anthony Gonçalves, Emmanuelle Charafe-Jauffret…
    Citation: BMC Cancer 2007 7:73
    Content type: Research article Published on:

  35. High levels of physical activity are associated with reduced risk of the blood cancer multiple myeloma (MM). MM is preceded by the asymptomatic stages of monoclonal gammopathy of undetermined significance (MGU...

    Authors: A Emery, S Moore, J Crowe, J Murray, O Peacock, D Thompson, F Betts, S Rapps, L Ross, D Rothschild-Rodriguez, A Arana Echarri, R Davies, R Lewis, DX Augustine, A Whiteway, Z Afzal…
    Citation: BMC Cancer 2024 24:174
    Content type: Research Published on:

  36. Ultra-hypofractionated regimens for definitive prostate cancer (PCa) radiotherapy are increasingly utilized due in part to promising safety and efficacy data complemented by greater patient convenience from a ...

    Authors: Sydney Wolfe, Marshall A. Diven, Ariel E. Marciscano, Xi Kathy Zhou, A. U. Kishan, M. L. Steinberg, Joseph A. Miccio, Philip Camilleri and Himanshu Nagar
    Citation: BMC Cancer 2023 23:923
    Content type: Study Protocol Published on:

  37. The biguanide metformin has been shown to not only reduce circulating glucose levels but also suppress in vitro and in vivo growth of prostate cancer. However, the mechanisms underlying the anti-tumor effects ...

    Authors: Emuejevoke Olokpa, Sammed N. Mandape, Siddharth Pratap and La Monica V. Stewart
    Citation: BMC Cancer 2022 22:1025
    Content type: Research Published on:

  38. Prostate cancer patients on androgen deprivation therapy (ADT) experience adverse effects such as lean mass loss, known as sarcopenia, fat gain, and changes in cardiometabolic factors that increase risk of met...

    Authors: Jacqueline K. Dawson, Tanya B. Dorff, E. Todd Schroeder, Christianne J. Lane, Mitchell E. Gross and Christina M. Dieli-Conwright
    Citation: BMC Cancer 2018 18:368
    Content type: Research article Published on:

  39. Activating mutations of the epidermal growth factor receptor (EGFR) confer sensitivity to the tyrosine kinase inhibitors (TKi), gefitinib and erlotinib. We analysed EGFR expression, EGFR mutation status and gene ...

    Authors: Caterina Peraldo-Neia, Giorgia Migliardi, Maurizia Mello-Grand, Filippo Montemurro, Raffaella Segir, Ymera Pignochino, Giuliana Cavalloni, Bruno Torchio, Luciano Mosso, Giovanna Chiorino and Massimo Aglietta
    Citation: BMC Cancer 2011 11:31
    Content type: Research article Published on:

  40. In previous study, we found that the content of medium-chain fatty acid Caprylic Acid (FFA C8:0) may be an important risk factor of obesity induced prostate cancer (PCa). However, the relationship between FFA ...

    Authors: Xue Li, Chenggang Yuan, Bingqi Yang, Huai Pang, Wei Li, Menghuan Li, Yihan Tang, Dingling Ma, Jianxin Xie, Jingzhou Wang and Jun Zhang
    Citation: BMC Cancer 2023 23:426
    Content type: Research article Published on:

  41. Stereotactic body radiotherapy (SBRT) is becoming increasingly used in treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy profiles when compared with longer courses o...

    Authors: Ting Martin Ma, James M. Lamb, Maria Casado, Xiaoyan Wang, T. Vincent Basehart, Yingli Yang, Daniel Low, Ke Sheng, Nzhde Agazaryan, Nicholas G. Nickols, Minsong Cao, Michael L. Steinberg and Amar U. Kishan
    Citation: BMC Cancer 2021 21:538
    Content type: Study protocol Published on:

  42. Spatial heterogeneity of prostate cancer-specific mortality in Pennsylvania remains unclear. We utilized advanced geospatial survival regressions to examine spatial variation of prostate cancer-specific mortal...

    Authors: Ming Wang, Emily Wasserman, Nathaniel Geyer, Rachel M. Carroll, Shanshan Zhao, Lijun Zhang, Raymond Hohl, Eugene J. Lengerich and Alicia C. McDonald
    Citation: BMC Cancer 2020 20:394
    Content type: Research article Published on:

  44. Obesity is associated with tumor aggressiveness and disease-specific mortality for more than 15 defined malignancies, including prostate cancer. Preclinical studies suggest that weight loss from caloric restri...

    Authors: Wendy Demark-Wahnefried, Jeffery W. Nix, Gary R. Hunter, Soroush Rais-Bahrami, Renee A. Desmond, Balu Chacko, Casey D. Morrow, Maria Azrad, Andrew D. Frugé, Yuko Tsuruta, Travis Ptacek, Scott A. Tully, Roanne Segal and William E. Grizzle
    Citation: BMC Cancer 2016 16:61
    Content type: Research article Published on:

    The Erratum to this article has been published in BMC Cancer 2017 17:71

  45. Basic leucine zipper ATF-like transcription factor 2 (BATF2) has been reported to participate in the occurrence and development of some malignancies. Herein, we aimed to explore the expression pattern and clin...

    Authors: Yingying Lin, Xusheng Zhou, Wei Peng, Jing Wu, Xiufeng Wu, Yan Chen and Zhaolei Cui
    Citation: BMC Cancer 2021 21:1062
    Content type: Research article Published on:

  46. Male breast cancer (MBC) is rare, accounting for only around 1% of all breast cancers. Most MBCs are hormone-driven. Not only the estrogen receptor (ER), but also other steroid hormone receptors, including the...

    Authors: Haruko Takuwa, Wakako Tsuji, Masayuki Shintaku and Fumiaki Yotsumoto
    Citation: BMC Cancer 2018 18:1282
    Content type: Case report Published on:

  48. Research and cancer care are closely intertwined; however, it is not clear whether physicians and nurses believe that clinical trials offer the best treatment for patients and, if so, whether this belief is ju...

    Authors: Zandra Engelbak Nielsen, Stefan Eriksson, Laurine Bente Schram Harsløf, Suzanne Petri, Gert Helgesson, Margrete Mangset and Tove E. Godskesen
    Citation: BMC Cancer 2020 20:401
    Content type: Research article Published on:

  49. Prostate cancer (PCa) is the second most common cancer among men. New imaging-modalities have increased the diagnosed patients with limited number of metastasis after primary curative therapy, introducing so-c...

    Authors: Giulia Marvaso, Delia Ciardo, Giulia Corrao, Sara Gandini, Cristiana Fodor, Dario Zerini, Damaris Patricia Rojas, Matteo Augugliaro, Giuseppina Bonizzi, Salvatore Pece, Federica Cattani, Ketti Mazzocco, Francesco Alessandro Mistretta, Gennaro Musi, Sarah Alessi, Giuseppe Petralia…
    Citation: BMC Cancer 2019 19:903
    Content type: Study protocol Published on:

  50. The prostate stroma is a key mediator of epithelial differentiation and development, and potentially plays a role in the initiation and progression of prostate cancer. The tumor-associated stroma is marked by ...

    Authors: Laura E Pascal, Young Ah Goo, Ricardo ZN Vêncio, Laura S Page, Amber A Chambers, Emily S Liebeskind, Thomas K Takayama, Lawrence D True and Alvin Y Liu
    Citation: BMC Cancer 2009 9:317
    Content type: Research article Published on:

Featured videos

View featured videos from across the BMC-series journals

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us